Imipramine: Depression, Other Uses, Heart Safety and Withdrawal

Imipramine is used to treat depressive illness. A clinician should explain why it is appropriate in the current situation, particularly when other antidepressants have been tried. Previous response, adverse effects, other medicines and physical health all influence the choice. The fact that a medicine is older does not establish that it is either ineffective or suitable for everyone. [1]

Clarify the main treatment goals. These might involve mood, interest, daily routine or the ability to participate in therapy and relationships. A change in sleep or energy alone does not demonstrate full recovery. The review should consider functioning and adverse effects together, with a clear route for advice if symptoms worsen.

Specialists sometimes consider imipramine for conditions such as panic disorder. Such use should be discussed in relation to the evidence and local authorization rather than assumed from the antidepressant label. One person’s successful treatment for panic does not establish that imipramine is the right medicine for another person’s anxiety. [1]

Ask which diagnosis the prescription addresses and what alternatives have been considered. Co-occurring symptoms may need their own assessment. The panic-disorder medication guide and depression medication hub explain why treatment plans should be linked to a specific condition rather than a general promise of calming.

Certain imipramine products have a role in nocturnal enuresis, or bedwetting, in children. NICE does not recommend tricyclics as first-line bedwetting treatment. It advises considering imipramine only after other approaches have not worked and after assessment by a professional experienced in persistent bedwetting. The risks, including overdose, require explicit discussion. [2]

This indication does not mean a child has depression, and it does not authorize use of any imipramine product for every pediatric condition. The exact formulation, age and specialist plan matter. Parents should not use another family member’s supply or increase treatment after a wet night. Relapse after a course needs review rather than an automatic independent restart.

Imipramine affects the reuptake of norepinephrine and serotonin and has other actions, including anticholinergic and antihistamine effects. It is converted partly into an active metabolite, desipramine. These pharmacological details help explain interactions and adverse effects, but do not provide a formula for predicting which patient will improve. [3]

The tricyclic class guide places imipramine alongside related medicines. Sharing a class does not make their indications, doses or formulations equivalent. Do not exchange it for amitriptyline, clomipramine or desipramine by matching the number on the package.

Imipramine is supplied in different forms in different markets. Products can differ in salt, concentration, ingredients and authorized uses. The cited UK oral solution has its own excipient precautions, and US capsule and tablet products should not be assumed to have identical indications. Confirm the actual preparation with the pharmacist. [3]

For a liquid, use the correct measuring device and check the concentration each time the product changes. Do not use a household spoon or copy the volume from an old bottle. A swallowing difficulty should prompt a formulation review rather than crushing or opening a preparation without checking whether that is appropriate.

The clinician needs to know about heart disease, fainting, seizures, glaucoma, urinary difficulty, liver disease and thyroid problems. A history of mania or hypomania is also important. The product information includes contraindications such as recent myocardial infarction and certain cardiac conduction problems. These are reasons for individualized selection rather than routine prescribing from a symptom list. [3]

Bring the complete prescription and supplement list, including medicines taken occasionally and recently stopped antidepressants. Describe alcohol or other substance use openly. The purpose is to identify interactions and monitoring needs, not to judge the person. Missing information can make a treatment that looks reasonable on paper unsuitable in practice.

Imipramine can affect cardiac conduction and heart rhythm. Risk can be greater with existing heart disease, certain other medicines or excessive exposure. The prescriber may consider an electrocardiogram and other assessments according to the clinical situation. Fainting, marked palpitations or chest symptoms should not be dismissed as anxiety. [4]

Blood pressure can also fall on standing, causing dizziness or falls. Explain when symptoms occur and whether another medicine or illness changed at the same time. Do not alter the prescription from a single home reading. Ask which signs need urgent contact and which measurements should be brought to the next review.

Dry mouth, constipation, blurred vision and urinary difficulty can occur. These effects may be more troublesome when other anticholinergic medicines are also used. Sedating antihistamines and non-prescription sleep products therefore belong in the medication review, not only the formal psychiatric prescriptions. [1]

Inability to pass urine needs urgent advice, and sudden severe eye pain with visual change requires urgent assessment because some medicines can trigger angle-closure glaucoma in susceptible people. Do not assume that every such symptom is an expected nuisance. A clinician should distinguish a manageable adverse effect from a potentially serious complication.

Drowsiness, dizziness or difficulty concentrating can affect daily activities. Do not drive or use dangerous machinery while impaired. Alcohol can add to sedation. Discuss shift work, caring responsibilities and other situations where reduced alertness creates a practical risk. The medication plan should fit ordinary life rather than ignore it.

Record what improved and what became harder. For example, better sleep accompanied by excessive daytime drowsiness needs a different review from improved mood without impairment. A prescriber can consider the regimen and other causes without treating every symptom as proof that the medicine must be stopped.

Changes in appetite, weight, sweating or sexual function can affect tolerability. These issues are valid reasons for review, even when they are difficult to discuss. The underlying illness and other medicines may contribute, so the timing and practical impact are more useful than assuming a single cause.

Bring a concise symptom record rather than testing the explanation by missing doses. Ask which symptoms may settle, which need investigation and what alternatives exist if a problem persists. Effective treatment should be compatible with an acceptable quality of life; adherence difficulties should not be dismissed as a lack of motivation.

New suicidal thoughts, severe agitation, hallucinations or a shift toward unusually elevated mood needs prompt clinical contact. Immediate suicidal danger requires emergency support. A seizure, collapse, serious allergic reaction or fever with confusion and marked muscle stiffness also needs urgent assessment. [4]

Jaundice, unexplained fever or significant signs of infection should be reported promptly. Tell the team about dose changes, missed treatment and newly added products. A person should not need to decide whether symptoms are psychiatric or physical before asking for help.

Tricyclic antidepressant overdose can be life-threatening because of effects on the heart, brain and circulation. Suspected excess ingestion requires immediate medical or poison-service advice even if symptoms have not appeared. Emergency help is required for collapse, a seizure, breathing difficulty or reduced consciousness. Do not induce vomiting or attempt a home remedy. [4]

Keep supplies secure and discuss appropriate quantities when safety is a concern. This is particularly important where children are present or when imipramine is prescribed for bedwetting. Safety arrangements should be supportive and transparent, not punitive. Return unused or discontinued medicine through an appropriate pharmacy disposal route.

MAO inhibitors are a particularly important interaction category. Other antidepressants can alter imipramine exposure or increase serotonergic risks. Medicines affecting heart rhythm, blood pressure or anticholinergic burden can also change the safety picture. The pharmacist should check the full list, including recent treatment and non-prescription products. [3]

Tell dental and surgical teams about imipramine before a procedure. Do not assume a short course of antibiotics, a cold remedy or a new pain medicine is too minor to matter. If several specialists are involved, ask who will coordinate the medication list and communicate changes.

Imipramine should usually be reduced through a planned process rather than abruptly discontinued. Withdrawal symptoms can overlap with recurrence of depression or anxiety, making the timing and pattern important. The need for a gradual change does not mean the medicine has the same addiction pattern as a substance used for intoxication.

Antidepressant switching may require additional precautions, especially involving MAOIs or medicines that alter tricyclic concentrations. Specialist Pharmacy Service provides clinician-facing guidance, but it is not a personal conversion schedule. Ask for a written plan and do not cross-taper or combine leftover supplies independently. [5]

Discuss pregnancy plans or breastfeeding before changing treatment. The assessment considers the actual product, previous illness and the effect of a possible switch. A medicine’s use for one indication or age group cannot be treated as a general assurance for another situation.

Older adults may be more affected by falls, confusion and anticholinergic effects, so the need for imipramine should be reviewed carefully against alternatives. This should not mean withdrawing effective psychiatric care without a replacement plan. The older-adult medication guide explains how to prepare for a balanced review.

Imipramine is not a medicine for unsupervised alcohol, opioid or benzodiazepine detox. Sedation and interactions can complicate substance-related care. A genuine co-occurring depressive or panic condition may still need treatment, but withdrawal assessment and ongoing addiction care are separate clinical tasks.

Tell the team about actual substance use, recent withdrawal and prescribed pain treatment. A residential service should coordinate with the existing prescriber before making changes. Neither automatic continuation without review nor an abrupt stop on admission is a substitute for an individualized plan.

Before a change of service, confirm the formulation, indication, supply and monitoring arrangements. A child receiving imipramine for bedwetting and an adult receiving it for depression need different review plans. The purpose should be visible in the handover so that the next clinician does not infer it from the medicine name alone.

At review, ask whether the original goal is being met, what harms are occurring and what the next step will be. A clear plan should name the responsible clinician and distinguish routine questions from emergencies. The medication-review checklist can help organize the discussion.

Does imipramine for bedwetting mean a child has depression?

No. Bedwetting is a separate indication with its own specialist assessment and safeguards. It should not be used to infer a psychiatric diagnosis.

Is it a sleeping tablet?

No. Sleepiness can occur, but the prescription should address a defined condition. It is not a general treatment for any night of poor sleep.

Can it be stopped when symptoms improve?

Discuss the next stage with the prescriber. Improvement, treatment duration, relapse risk and withdrawal all influence the stopping plan.

• [1] MedlinePlus: Imipramine.
• [2] NICE CG111: Bedwetting in under 19s.
• [3] Electronic Medicines Compendium: Imipramine oral solution product information.
• [4] DailyMed: Imipramine hydrochloride prescribing information.
• [5] NHS Specialist Pharmacy Service: Tricyclic antidepressant switching.